滤泡性淋巴瘤中 CD19 靶向治疗的最新进展。
Recent developments in CD19-targeted therapies for follicular lymphoma.
机构信息
Department of Medicine/Hematology Oncology, University of South Florida, Tampa, FL, USA.
Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.
出版信息
Expert Opin Biol Ther. 2024 Oct;24(10):1049-1055. doi: 10.1080/14712598.2024.2404100. Epub 2024 Sep 18.
INTRODUCTION
CD19 has emerged as an important and novel therapeutic target in follicular lymphoma. CD19-directed therapies, including monoclonal antibodies, bispecific antibodies, and CAR T-cell therapies, offer promising avenues for treating follicular lymphoma and improving outcomes.
AREAS COVERED
We review the role and rationale of targeting CD19 in follicular lymphoma and different interventions of CD19 targeting, such as cell therapy, bispecific antibodies, antibody-drug conjugates, and monoclonal antibodies. We finalize with a discussion on how these therapies may influence the treatment landscape of follicular lymphoma.
EXPERT OPINION
CD19 is an attractive target for therapeutic development in follicular lymphoma. Given its effectiveness, it will continue to move forward as a promising therapy for this disease.
简介
CD19 已成为滤泡性淋巴瘤的一个重要且新颖的治疗靶点。CD19 导向疗法，包括单克隆抗体、双特异性抗体和 CAR-T 细胞疗法，为治疗滤泡性淋巴瘤和改善预后提供了有前途的途径。
涵盖领域
我们回顾了靶向 CD19 在滤泡性淋巴瘤中的作用和原理，以及 CD19 靶向的不同干预措施，如细胞疗法、双特异性抗体、抗体药物偶联物和单克隆抗体。最后，我们讨论了这些疗法如何影响滤泡性淋巴瘤的治疗格局。
专家意见
CD19 是滤泡性淋巴瘤治疗开发的一个有吸引力的靶点。鉴于其有效性，它将继续作为该疾病的一种有前途的治疗方法向前发展。
Zotero 插件